Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications
Conditions
Interventions
Intervention1: Nil: Nil
Control Intervention1: Nil: Nil
Sponsors
Torrent Pharmaceuticals Ltd,
Eligibility
Inclusion criteria
Inclusion criteria: 1) Uncontrolled T2DM >= 7% HbA1c, FBG > 100 mg/dL & PPBG >= 200 mg/dL 2) Patients of either sex, above 18 years of age with T2DM and who had received treatment with FDC of glimepiride, metformin sustained release (SR) and voglibose of any strength
Exclusion criteria
Exclusion criteria: 1) Patients who had incomplete data or any condition that according to the discretion of the investigator indicated that the patient is not suitable for the study were excluded. Duration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) HbA1c outcome at 12 week 2) FBG outcome at 4 week 3)PPBG Outcome at 4 week ( 1 or 2 hour) 4)Safety Assessment at 12 week 5) Utilization pattern of Voglibose + Metformin + Glimepiride FDCTimepoint: at 4 & 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient complianceTimepoint: At week 12;Physician Global AssessmentTimepoint: At week 12;PPBG outcome for high risk cases of T2DM with CVDTimepoint: At week 4;Suspected underlying cause of T2DMTimepoint: At week 12;Trend of Co-prescriptions for Type 2 Diabetes Mellitus other than triple drug FDCTimepoint: At week 12 | — |
Countries
India
Contacts
Public ContactDr Rathish Nair PhD MBA
Torrent Pharmaceuticals Ltd
Outcome results
None listed